Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
https://finance.yahoo.com/news/2-ultra-high-growth-biotech-1...

Buying biotech stocks in May is rarely a good idea. This class of equities, after all, tends to fade in a big way around this time year. However, there are some outstanding exceptions to this general rule of thumb.

For instance, Amicus Therapeutics (NASDAQ: FOLD) and Array BioPharma (NASDAQ: ARRY) are two biotech stocks poised to continue churning higher -- even during this historically weak period of the year for the industry as a whole. Here's why investors might want to add these two top growth stocks to their portfolios soon.


Array: An emerging cancer treatment play

Cancer is easily the largest pharmaceutical market in terms of annual sales. Even so, this massive market also happens to be the fastest growing as well, thanks to the combination of novel treatments opening up new segments of the space and the ever-rising incidence rate for most malignancies across the globe. As a result, companies that successfully navigate the risky clinical trials process to bring a well-differentiated oncology treatment to market tend to be highly coveted by investors. Array BioPharma fits into this mold to perfection.

Last year, the Food and Drug Administration (FDA) approved its advanced BRAF-mutant melanoma combo treatment consisting of Braftovi and Mektovi. Since launch, this unique combination therapy has quickly become an important new weapon in the battle against BRAF-mutated skin cancer. As proof, Array reported $35.1 million in net sales during the most recent quarter. That's an impressive haul for a drug that hasn't even been on the market for a full year yet. Array thinks this first indication could eventually push the therapy's sales close to blockbuster territory (> $1 billion per year), although Wall Street largely thinks the drug will ultimately top out at around $500 million.

Array, though, has even bigger plans for its first major cancer treatment. The company recently reported positive late-stage results for Braftovi and Mektovi -- when used in conjunction with another compound called Erbitux -- in patients with BRAF-mutated colorectal cancer. The FDA has already granted this triplet therapy breakthrough therapy designation, which should shorten its review time to roughly half a year. So, with Array on track to file a supplemental New Drug Application in the second half of this year for this unique triplet regimen, the company could see a sizable jump in its top line in 2020 and beyond. Backing this assertion, EvaluatePharma, a top industry analytics firm, has the combo's peak sales for advanced colorectal cancer pegged at approximately $700 million.



My daily chart for ARRY:

http://schrts.co/zuyJhqSD
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.